As filed with the Securities and Exchange Commission on March 29, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Molecular Templates, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 94-3409596 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
9301 Amberglen Blvd, Suite 100
Austin, Texas 78729
(512) 869-1555
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Molecular Templates, Inc. 2018 Equity Incentive Plan
(Full Title of the Plan)
Eric E. Poma, Ph.D.
Chief Executive Officer and Chief Scientific Officer
Molecular Templates, Inc.
9301 Amberglen Blvd, Suite 100
Austin, Texas 78729
(512) 869-1555
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
William C. Hicks, Esq.
Matthew J. Gardella, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement registers an aggregate of 2,252,202 additional shares of common stock, par value $0.001 per share (Common Stock), of Molecular Templates, Inc. (the Registrant) reserved for issuance under the Molecular Templates, Inc. 2018 Equity Incentive Plan, as amended (the 2018 Plan), consisting of an increase of 2,252,202 shares reserved under the 2018 Plan effective January 1, 2022 by operation of the 2018 Plans evergreen provision. This Registration Statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (333-254484), Form S-8 (File No. 333-237148), Form S-8 (File No. 333-230617) and Form S-8 (File No. 333-225826) are effective. Pursuant to Instruction E of Form S-8, the information contained in the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June 22, 2018, as amended on August 3, 2018 (File No. 333-225826), Form S-8 filed with the Securities and Exchange Commission on March 29, 2019 (File No. 333-230617), Form S-8 filed with the Securities and Exchange Commission on March 13, 2020 (File No. 333-237148) and Form S-8 filed with the Securities and Exchange Commission on March 19, 2021 (File No. 333-254484) is incorporated by reference herein.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
Exhibit Index
* | Filed herewith. |
# | Indicates a management contract or compensatory plan. |
3
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Austin, Texas on March 29, 2022.
MOLECULAR TEMPLATES, INC. | ||
By: | /s/ Eric E. Poma, Ph.D. | |
Eric E. Poma, Ph.D. | ||
Chief Executive Officer and Chief Scientific Officer |
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Eric E. Poma, Ph.D., and Sean McLennan, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Eric E. Poma, Ph.D. Eric E. Poma, Ph.D. |
Chief Executive Officer and Chief Scientific Officer and Director (Principal Executive Officer) |
March 29, 2022 | ||
/s/ Sean McLennan Sean McLennan |
Interim Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
March 29, 2022 | ||
/s/ Harold E. Selick, Ph.D. Harold E. Selick, Ph.D. |
Director |
March 29, 2022 | ||
/s/ Jonathan Lanfear Jonathan Lanfear |
Director |
March 29, 2022 | ||
/s/ David Hirsch, M.D., Ph.D. David Hirsch, M.D., Ph.D. |
Director |
March 29, 2022 | ||
/s/ David R. Hoffmann David R. Hoffmann |
Director |
March 29, 2022 | ||
/s/ Kevin M. Lalande Kevin M. Lalande |
Director |
March 29, 2022 | ||
/s/ Scott Morenstein Scott Morenstein |
Director |
March 29, 2022 | ||
/s/ Corazon Corsee Sanders, Ph.D. Corazon Corsee Sanders, Ph.D. |
Director |
March 29, 2022 | ||
/s/ Gabriela Gruia, M.D. Gabriela Gruia, M.D. |
Director |
March 29, 2022 |
4
EXHIBIT 5.1
|
One Financial Center Boston, MA 02111 617 542 6000 mintz.com |
March 29, 2022
Molecular Templates, Inc.
9301 Amberglen Blvd, Suite 100
Austin, Texas 78729
Ladies and Gentlemen:
We have acted as legal counsel to Molecular Templates, Inc., a Delaware corporation (the Company), in connection with the preparation and filing with the Securities and Exchange Commission (the Commission) of a Registration Statement on Form S-8 (the Registration Statement), pursuant to which the Company is registering the issuance under the Securities Act of 1933, as amended (Securities Act), of an aggregate of 2,252,202 shares (the Shares) of the Companys common stock, $0.001 par value per share (Common Stock), in accordance with the terms of the Molecular Templates, Inc. 2018 Equity Incentive Plan (the Plan). This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.
In connection with this opinion, we have examined the Companys Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the Companys officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.
In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such copies, and the truth and correctness of any representations and warranties contained therein. In addition, we have assumed that the Company will receive any required consideration in accordance with the terms of the Plan.
Our opinion expressed herein is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
Based upon the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.
BOSTON LONDON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO WASHINGTON
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
MINTZ Molecular Templates, Inc. March 29, 2022 Page 2 |
|
We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
Very truly yours,
/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2018 Equity Incentive Plan of Molecular Templates, Inc. of our report dated March 29, 2022, with respect to the consolidated financial statements of Molecular Templates, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
Austin, Texas |
March 29, 2022 |
EXHIBIT 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Molecular Templates, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered
Security Type | Security Class Title | Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||
Equity | Common Stock, par value $0.001 per share | 457(c) and 457(h) |
2,252,202(1) | $2.55(2) | $5,743,115(2) | $0.0000927 | $532.39 | |||||||
Total Offering Amount | $5,743,115 | $532.39 | ||||||||||||
Total Fee Offsets | | |||||||||||||
Net Fee Due | $532.39 |
(1) | The number of shares of common stock, par value $0.001 per share (Common Stock), of Molecular Templates, Inc. (the Registrant) stated above consists of additional shares of common stock available for issuance under the Molecular Templates, Inc. 2018 Equity Incentive Plan, as amended (the 2018 Plan) by operation of the 2018 Plans evergreen provision. The maximum number of shares which may be sold upon the exercise of such options or issuance of stock-based awards granted under the 2018 Plan are subject to adjustment in accordance with certain anti-dilution and other provisions of the 2018 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions. |
(2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future issuance under the 2018 Plan is based on the average of the high and the low price of Registrants Common Stock as reported on the Nasdaq Global Select Market on March 22, 2022, a date within five business days prior to filing this Registration Statement. |
C*